The Company’s proprietary platform targets fat taste receptors (CD36 and GPR120) — a novel mechanism that naturally stimulates the body’s endogenous release of satiety hormones including GLP-1, CCK, and PYY, without the need for exogenous hormone administration.
This approach directly addresses the key limitations of current GLP-1 therapies: weight rebound after discontinuation, loss of lean muscle mass, and gastrointestinal side effects. Preclinical data demonstrate up to 40% reduction in food intake in obese animal models and 50% reduction in post-semaglutide weight rebound. Clinical data from 87+ subjects show a favorable safety profile with no serious adverse events.
The Company’s pipeline includes two lead molecules (NKS-3 and NKS-5) for obesity, an anti-inflammatory program, and next-generation agonists in early development. EktaH is ISO 9001:2015 certified and is supported by an international Scientific Advisory Board. Founded in 2021, EktaH is headquartered in Dijon, France.


EKTAH

Org chart

Teams

Offices

EKTAH

Org chart

Teams

Offices

Related companies